Association of APOC3 polymorphisms with both dyslipidemia and lipoatrophy in HAART-receiving patients.
The incidence and the magnitude of lipodystrophy and dyslipidemia in HIV-treated people reported in previous studies are very variable. Several predisposing factors have been identified, but there are few data on genetic factors. To search for a correlation between APOC3 polymorphisms and lipid disorders and lipodystrophy in HIV patients under d4T and protease inhibitors (PI)-containing HAART, we designed a monocenter, cross-sectional study in a University Hospital in Southern France during the period 2001-2004. Forty patients under HAART were included, with d4T for > or = 2 years and PI for > or = 1 year. We determined body mass composition by DXA, lipoprotein markers, and the -455/-482 apo C3 genotypes. Carriers of APOC3 variant alleles (-455 1/-482 1) displayed higher levels of triglycerides (3.72 vs. 2.57 mmol/liter), apo C3 (45.3 vs. 34.5 mg/liter), and apo E (130.2 vs. 66.5 mg/liter) and a lower fat mass (13.9 vs. 19.7%) than patients with nonvariant alleles (-455 0/-482 0). APOC3 polymorphisms might be associated with both dyslipidemia and lipoatrophy in HAART-treated patients.
Bonnet
Eric
E
INSERM U563, Centre de Physiopathologie de Toulouse-Purpan, and Université Toulouse III Paul Sabatier, IFR30, Toulouse, F-31300, France. bonnet.e@chu-toulouse.fr
Bernard
Jacques
J
Fauvel
Josette
J
Massip
Patrice
P
Ruidavets
Jean-Bernard
JB
Perret
Bertrand
B
D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D053305:Apolipoprotein C-III / Q000235:genetics*; D001823:Body Composition; D050218:Body Fat Distribution; D003430:Cross-Sectional Studies; D050171:Dyslipidemias / Q000235:genetics*; D005602:France; D005787:Gene Frequency; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D039682:HIV-Associated Lipodystrophy Syndrome / Q000235:genetics*; D006801:Humans; D008074:Lipoproteins / Q000097:blood; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D018119:Stavudine / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood
D019380:Anti-HIV Agents; D053305:Apolipoprotein C-III; D017320:HIV Protease Inhibitors; D008074:Lipoproteins; D014280:Triglycerides; D018119:Stavudine